The activity of tyrosine kinase inhibitors on clear cell renal cell carcinoma tumor initiating cells in hypoxic microenvironment : 01
Preexisting hypertension is associated with advanced tumor stage but improved cancer specific survival in clear cell renal cell carcinoma : 02
Tumor suppressor screens of 3p chromatin modulators link BAP1 mutations to poor clinical outcomes in clear cell renal cell carcinoma : 03
Hereditary and sporadic type 2 papillary renal cell carcinoma converge at NRF2 activation phenotype : 04
Improved outcomes with sunitinib alternative schedule compared to traditional schedule: a single-center retrospective review : 05
Isolation of renal cell carcinoma cells from blood samples using the vertical immiscible filtration assisted by surface tension (VerIFAST) microfluidic platform : 06
Pathologic validation of renal cell carcinoma histology in the surveillance, epidemiology, and end results program : 07
Succinate dehydrogenase kidney cancer (SDH-RCC): an aggressive example of the Warburg effect in cancer : 08
Clinical activity and safety of antiprogrammed death-1 (PD-1) (BMS936558/MDX-1106/ONO-4538) in patients (pts) with previously treated, metastatic renal cell carcinoma (mRCC) : 09
Tivozanib pharmacokinetic (PK)/ pharmacodynamic (PD) analysis of blood pressure and soluble vascular endothelial growth factor receptor 2 (sVEGFR2) in patients with advanced renal cell carcinoma (RCC) : 10
Progression free survival (PFS) and overall survival (OS) in patients receiving 3 targeted therapies (TTs) for metastatic renal-cell carcinoma (mRCC) : 11
Predictive factors of progression free survival (PFS) and overall survival (OS) in patients treated with tirosine kinase inhibitors (TKIs) for advanced renal cell carcinoma (A-RCC): a retrospective analysis of a mono-institutional series : 12
A phase 1 study of BMS-936558 plus sunitinib or pazopanib in patients with metastatic renal cell carcinoma : 13
Examining everolimus in a study of tuberous sclerosis complex (TSC) trial (EXIST-2): updated safety results : 14
B7H1 expression and association with clinical response to sunitinib therapy in metastatic renal cell carcinoma (mRCC) patients : 15
Cardiology co-management improves blood pressure control in patients with anti-VEGF-induced hypertension : 16
Urine biomarkers to diagnose renal cell carcinoma : 17
Detection of circulating tumor cells in advanced renal cell carcinoma patients using microfilter-based capture : 18
Inhibitory effects of pyrrole-imidazole polyamide targeting MMP9 for invasiveness of renal carcinoma cells : 19
Precision of excision/reconstruction and recovery from ischemia: quality parameters for functional recovery after partial nephrectomy : 20
Role of stereotactic body radiotherapy in the management of non-surgical patients : 21
Association of renal cell carcinoma (RCC) and hematological malignancy (HM) : 22
Critical analysis of frozen section deep parenchymal margin sampling during robot-assisted laparoscopic partial nephrectomy : 23
Next-generation sequencing reveals genomic determinants of long-term response to mTOR inhibitors in patients with advanced RCC : 24
Identification of protein expression signatures in clear renal cell carcinoma histological type : 25
Profiling signaling pathways in formalinfi xed and paraffin-embedded renal cell carcinoma tissues : 26
The functional role of CA9 and glucose transporters (GLUT) in human renal cell carcinoma : 27
Clinicopathological feature of T2b renal cell carcinoma : 28
Treatment patterns in metastatic renal cell carcinoma in the US: a retrospective chart review in community oncology practices : 29
Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: results from a Phase III randomized, open-label, multicenter trial : 30
Role of PPARα in proliferation and cell cycle regulation in human renal cell carcinoma : 31
Open-label phase 2 trial of second-line everolimus in patients with metastatic renal cell carcinoma (mRCC) : 32
The lipid metabolomic profile of clear cell renal cell carcinoma (CCRCC) : 33
Impact of age on treatment trends and clinical outcome in patients with metastatic renal cell carcinoma : 34
Detailed comparison of the safety of tivozanib versus sorafenib in patients with advanced/metastatic renal cell carcinoma (mRCC) from a Phase III trial : 35
Identifying SETD2 -epigenetically regulated pathways to target kidney cancer metastases : 36
Number of sites of metastases solely predicts survival of cytoreductive nephrectomy for metastatic renal cell carcinoma: revisiting lessons learned from the past : 37
Modulation of TRiC/CCT and proteasome regulates VHL proteostasis and functionality : 38
A description of the surgical experience in children, adolescents and young adults with renal cell carcinoma: a report from the Children's Oncology Group Study AREN 03B2 : 39
Epidemiology and characterization of pediatric and adolescent renal cell carcinoma: a report from the Children's Oncology Group Study AREN 03B2 : 40
Small sized clear cell typed renal cell carcinoma with liver, lung, bone and bone marrow metastasis : 41
Percutaneous biopsy of kidney tumors at Roswell Park Cancer Institute (RPCI) : 42
Ovarian and thyroid metastases from renal cell carcinoma (RCC) successfully treated with metastectomy : 43